The European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) for Diphenhydramine Hydrochloride, API in Anti-Histamine therapy to Supriya Lifescience Limited.

This will be an added advantage for Supriya Lifescience Limited in the European market. The global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.